CALCOL, Inc. (CLCL) 股票表現
查看CALCOL, Inc.的財務表現,包括市值、價格變動百分比、本益比,以及歷史和當前股價。
前收盤價0.00
52週高點0.00
打開0.00
52週低點0.00
資金流向0.00%
本益比0%
T/O0.00b
市淨率0%
離職率0.00%
市值0.00b
股息0
總股數0.99b
股息殖利率0%
批量大小1
CALCOL, Inc.公司簡介
THE COMPANY IS A DELAWARE USA HOLDING COMPANY WITH CHINA AND BVI SUBSIDIARIES FOR US AND CHINA INVESTMENTS IN SOFT DRINKS, ENERGY DRINKS AND PHARMACEUTICALS WITH OFFICES IN BEIJING, CHINA, AND BEACHWOOD, OHIO USA.
THE COMPANY OWNS AND OPERATES MALIBU-COLA BEVERAGE CO. LTD. (CHINA) BEIJING AND KULONG ENERGY BEVERAGE COMPANY INC. (BVI) WHICH MAKES AND SELLS ITS TRADEMARKED MALIBU-COLA (PRODUCED UNDER LICENSE FROM RC COLA INTERNATIONAL DIVISION OF COTT BEVERAGES USA INC.), MALIBU SUNRISE ORANGE, MALIBU SURFS UP LEMON LIME, MALIBU LEMON SQUEEZE, AND MALIBU DIET COLA IN CHINA. THE COMPANY HAS SUCCESSFULLY MARKETED ITS TRADEMARKED "MALIBU" BRANDED PRODUCTS IN CHINA THROUGH SALES CONTRACTS WITH WAL-MART, TRUST-MART, LOTUS, TESCO, CARREFOUR, AND OTHER MAJOR RETAIL CHAINS AS WELL AS LOCAL SUPERMARKETS.
THROUGH ITS SUBSIDIARY COMPANIES, BEIJING KULONG ENERGY TRADING CO. LTD. AND KULONG ENERGY BEVERAGE COMPANY INC. (BVI), THE COMPANY ALSO MANUFACTURES ITS OWN PROPRIETARY RECIPES AND SOLELY OWNED INTERNATIONALLY TRADEMARKED KULONG FRUIT FLAVORED VITAMIN DRINK (WITH GUARANA, TAURINE, B-VITAMINS, AND FRUIT FLAVORS) FOR SALE IN CHINA, AND KULONG VITAMIN-ENRICHED ENERGY DRINK (WITH CAFFEINE, GUARANA, TAURINE, GLUCOURONOLACTONE, GINSENG, ACAI FRUIT, GOJI BERRY, MANGOSTEEN,B-VITAMINS, ELECTROLYTES, AND FRUIT FLAVORS) FOR SALE IN THE USA AND INTERNATIONALLY (EX-CHINA).THE COMPANY CURRENTLY MANUFACTURES IN USA AND PLANS TO DISTRIBUTE KULONG ENERGY DRINK AND KULONG ENERGY DRINK ZERO IN USA (LABELLED "MADE IN USA") THROUGHOUT THE USA, CANADA, MEXICO, CENTRAL AND SOUTH AMERICA, CARIBBEAN, ALL OF EU, JAPAN AND HONG KONG AND TAIWAN, ISRAEL AND THE MIDDLE EAST.
THE COMPANY ALSO OWNS A METHOD OF PRODUCTION OF CHEMICALLY SYNTHETIC LARGE SCALE GMP PHARMACEUTICAL GRADE DELTA-9-TETRAHDYROCANNABINOL (THC) AND DELTA-8-TETRAHYDROCANNABINOL (CBD), AND OWNS THE DISTRIBUTION RIGHTS. THE COMPANY IS PLANNING FURTHER RESEARCH OF THC AND CBD PHARMACEUTICALS WITH THE OBJECTIVE TO DEVELOP FOR MANUFACTURE AND SALE A DOSAGE FORM AND MEDICAL DEVICE FOR PRECISE CLINICAL ADMINISTRATION BY PRESCRIPTION OF THESE MEDICATIONS FOR TREATMENT OF VARIOUS MEDICAL CONDITIONS.